Strides Pharma ScienceNSE:STAR -2.62%67 Days Payable is 222.86 as of Mar. 2026, which is 3% above its 10-year median of 216.47. GuruFocus rates NSE:STAR with a GF Score™ of 67/100 and a GF Value™ of ₹773.22 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 920 Drug Manufacturers companies, Strides Pharma Science ranks better than 86.96% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Strides Pharma Science's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Strides Pharma Science Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Strides Pharma Science's Days Payable distribution charts can be found below:
* The bar in red indicates where Strides Pharma Science's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Strides Pharma Science's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Strides Pharma Science (NSE:STAR) has a Days Payable of 222.86 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Strides Pharma Science and its competitors. This is near median its historical median of 216.47. Over the past decade, Strides Pharma Science's Days Payable has ranged from 173.66 to 254.25. According to the industry distribution chart, Strides Pharma Science ranks #120 out of 920 companies in the Drug Manufacturers industry, placing it in the top 13%.
Is Strides Pharma Science's Days Payable too high?
Strides Pharma Science's current Days Payable of 222.86 is near median its 10-year median of 216.47. Over the past 10 years, this metric has ranged from a low of 173.66 to a high of 254.25. The Drug Manufacturers industry median Days Payable is 90.84. Strides Pharma Science's value of 222.86 is 145.3% above this industry median. Based on the distribution chart, Strides Pharma Science ranks #120 out of 920 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Strides Pharma Science has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Strides Pharma Science's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Strides Pharma Science ranks #120 out of 920 companies for Days Payable. This places Strides Pharma Science in the top 13% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.84. Strides Pharma Science's value of 222.86 is 145.3% above this benchmark. Historically, Strides Pharma Science's own Days Payable has ranged from 173.66 to 254.25 over the past decade. While the company's 10-year median is 216.47 vs. the industry median of 90.84, Strides Pharma Science has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Strides Pharma Science's current Days Payable of 222.86 is 145.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Strides Pharma Science and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Strides Pharma Science's current Days Payable is 222.86, which is near median its own 10-year median of 216.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strides Pharma Science stock overvalued right now?
Based on GuruFocus' analysis, Strides Pharma Science (NSE:STAR) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹773.22, compared to a current price of ₹1,082.20 — trading 40% above its estimated fair value. The current Days Payable is 222.86, which is near median its 10-year median of 216.47 and 145.3% above the Drug Manufacturers industry median of 90.84. Strides Pharma Science's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Strides Pharma Science (NSE:STAR), the current Days Payable is 222.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Strides Pharma Science (NSE:STAR) Overvalued in 2026?
Based on GuruFocus' analysis, Strides Pharma Science stock appears to be overvalued.
The current stock price of ₹1,082.20 is trading 40% above its estimated GF Value™ of ₹773.22.
GuruFocus considers Strides Pharma Science to be Significantly Overvalued.
Key valuation signals for NSE:STAR:
Days Payable: 222.86 (near median its 10-year median of 216.47)
GF Value™: ₹773.22 vs. price of ₹1,082.20 (40% above fair value)
Industry Position: 145.3% above the Drug Manufacturers median (#120 of 920)
No single metric tells the full story. See the NSE:STAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Strides Pharma Science Ltd develops and manufactures a wide range of IP-led niche pharmaceutical products. Its diverse portfolio spans complex generics across multiple dosage forms, including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. It also manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for its institutional business. The customers for this business include institutionally funded aid projects and procurement agencies. With its R&D, integration, and distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets. Geographically, it generates maximum revenue from North America.
67GF Score
Get the complete analysis for NSE:STAR
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:STAR has been successfully added to your 
